Schrodinger (SDGR) said Monday it received an additional $9.5 million from the Bill & Melinda Gates Foundation to accelerate its initiative to expand its computational platform for early toxicology risk prediction in drug discovery.
The additional funding, which follows the initial $10 million grant from the foundation in July, enables Schrodinger to access relevant experimental structures faster and extends the funding for the initiative to April 2026, Schrodinger said.
The company said the initiative aims to reduce development failures and improve drug safety, and once developed, the technology will be available to Gates Foundation grantees and Schrodinger's customers.
The majority of revenue related to the additional funding is anticipated to be recognized next year, the company said.
Schrodinger shares were down more than 5% in recent Monday trading.
Price: 17.55, Change: -0.99, Percent Change: -5.34
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。